Document is current
Any future updates will be listed below
-
Authors
Kinguchi, Sho
Wakui, Hiromichi
Ito, Yuzuru
Kondo, Yoshinobu
Azushima, Kengo
Osada, Uru
Yamakawa, Tadashi
Iwamoto, Tamio
Yutoh, Jun
Misumi, Toshihiro
Aoki, Kazutaka
Yasuda, Gen
Yoshii, Taishi
Yamada, Takayuki
Ono, Syuji
Shibasaki-Kurita, Tomoko
Hosokawa, Saho
Orime, Kazuki
Hanaoka, Masaaki
Sasaki, Hiroto
Inazumi, Kohji
Yamada, Taku
Kobayashi, Ryu
Ohki, Kohji
Haruhara, Kotaro
Kobayashi, Yusuke
Yamanaka, Takeharu
Terauchi, Yasuo
Tamura, Kouichi
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000018930 at UMIN JapanDocuments that mention this clinical trial
Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)
https://doi.org/10.1186/s12933-019-0912-3
-
Funding
Funding for this research was provided by:
Salt Science Research Foundation (18C4, 19C4)
Yokohama City University research grant “KAMOME Project”
Yokohama Foundation for Advancement of Medical Science
Uehara Memorial Foundation
Kanae Foundation for the Promotion of Medical Science
Japan Society for the Promotion of Science
SENSHIN Medical Research
Banyu Life Science Foundation International
The Cardiovascular Research Fund, Tokyo, Japan
the Strategic Research Project of Yokohama City University
Japan Agency for Medical Research and Development (The Translational Research program, Strategic PRomotion for practical application of INnovative medical Technology (TR-SPRINT))
- License Information
-
More Information
Article History
Received: 17 May 2019
Accepted: 12 August 2019
First Online: 27 August 2019
Ethics approval and consent to participate
: This study complied with the ethical principles of the Declaration of Helsinki, and was approved by the institutional ethics committee at each participating hospital. All patients provided written informed consent prior to participation.
: All the authors agree.
: UO has received honoraria for speaking from Astra Zeneca and Ono Pharmaceutical Co. Ltd. TY has received research grant support from Astra Zeneca and an honorarium for speaking from Ono Pharmaceutical Co. Ltd. TM has received research grant support from Ono Pharmaceutical Co. Ltd. KA has received research grant support from Astra Zeneca. TY has received honoraria for speaking from Astra Zeneca and Ono Pharmaceutical Co. Ltd. TY has received research grant support from Ono Pharmaceutical Co. Ltd. and honoraria for speaking from Astra Zeneca and Ono Pharmaceutical Co. Ltd. YT has received research support from Ono Pharmaceutical Co. Ltd. and honoraria for speaking from Astra Zeneca and Ono Pharmaceutical Co. Ltd., and has participated in an advisory board for AstraZeneca. KT has received honoraria for speaking from Astra Zeneca and Ono Pharmaceutical Co. Ltd., and has participated in an advisory board for AstraZeneca.
